-

Better Therapeutics to Participate in Two Upcoming Investor Events

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:

  • A virtual fireside chat hosted by LifeSci Capital on January 26 from 12 – 1 p.m. EST. The management team will discuss the current treatment paradigm for cardiometabolic diseases, Better Therapeutics’ approach for treating behavioral root causes using prescription digital therapeutics (PDT), and its lead candidate BT-001, a PDT for treating uncontrolled type 2 diabetes in adults, currently undergoing a potentially pivotal trial. To register for the call, please email Robert Fromberg (rfromberg@lifescicapital.com).
  • The Cowen 42nd Annual Health Care Conference taking place March 7 – 9 in Boston, MA, including a fireside chat on Monday, March 7th, from 2:10-2:40 pm EST.
  • A replay of both firesides will be available on the Presentations and Events section on the Better Therapeutics investor site (www.investors.bettertx.com) for approximately 90 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com

BTTX-PR

Contacts

Investor Relations:
Mark Heinen
IR@bettertx.com

Media:
Cassidy McClain
Cassidy.McClain@canalecomm.com
619.849.6009

Better Therapeutics, Inc.

NASDAQ:BTTX

Release Versions
$Cashtags

Contacts

Investor Relations:
Mark Heinen
IR@bettertx.com

Media:
Cassidy McClain
Cassidy.McClain@canalecomm.com
619.849.6009

Social Media Profiles
More News From Better Therapeutics, Inc.

Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in collaboration with MedEd On The Go, today announced the availability of an on-demand, educational symposium entitled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.” The on-demand educational symposium is moderate...

Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs)

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, announces a new code from the Center for Medicare and Medicaid Services (CMS) that paves the way for reimbursement of these therapies. CMS recently created new, Level II Healthcare Common Procedure Coding Systems (HCPCS) codes for prescription digital beha...

Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, today announced the first patient has been enrolled in a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-00...
Back to Newsroom